Five-year study shows SRT-100 benefits patients with non-melanoma skin cancer

Sensus Healthcare announced topline results from a five-year retrospective study of non-melanoma skin cancer (NMSC) patients treated with Superficial Radiation Therapy (SRT) (ClinicalTrials.gov Identifier: NCT03693937). The study, which was conducted across four U.S. sites, showed a 98.9 percent cure rate among 516 male and female patients. These patients had a collective total of 776 NMSC lesions treated with Sensus' SRT-100. Most patients in the study population were elderly with a mean age of 79 years. Kaplan-Meier estimates of cumulative recurrence rates of all tumors at both 2 and 5 years were 1.1 percent; basal cell carcinoma cumulative recurrence rates at five years were 1.2 percent, and squamous cell carcinoma cumulative recurrence rates were 0.9 percent.

Comment: SRT is a low energy radiotherapy that goes no deeper than the thickness of the skin. It is a proven non-invasive procedure that has been used to treat non-melanoma skin cancer for over 50 years and is highly recognized and reimbursable. Because the superficial x-rays concentrate radiation dose on the skin surface, the treatment has several advantages over surgical procedures. The SRT 100 is portable, flexible, and cost-effective, making it a viable option for private dermatology and oncology practices, as well as hospitals and multi-locale healthcare providers. The device uses SharpBeam technology, where only the targeted lesion is being treated, while the surrounding and underlying healthy tissue is spared.